CDK8 and colorectal adenocarcinoma: Pharmacological screening for potent Cdk8 inhibitors is of utmost importance since, in line with its oncogenic role, Cdk8 has been identified as the down-stream effector of the Wnt/β-catenin pathway in colorectal adenocarcinoma [55,57,126,127].